David Hough

Head of Clinical Development @ Mindstate Design Labs arrow icon

loader linkedin icon See Linkedin

About David Hough

David Hough is the Head of Clinical Development known for leading the first FDA-approved therapeutic in the hallucinogen classes and previously served as Vice President at Janssen.

Known information

David Hough currently holds the position of Head of Clinical Development and is recognized for his leadership in developing the first and only FDA-approved therapeutic within the hallucinogen classes. Prior to his current role, he was a Vice President at Janssen, a subsidiary of Johnson & Johnson, where he dedicated 17 years in various leadership capacities. During his tenure at Janssen, Hough was instrumental as the SPRAVATO (esketamine) compound development team leader, managing the development program through two severe mood disorders indications and overseeing all facets of the program including medical, scientific, manufacturing, quality, preclinical, and commercial aspects. Additionally, he was the schizophrenia disease area leader and led the development team for paliperidone, significantly contributing to the development of oral INVEGA (paliperidone) and its extended-release formulations, INVEGA SUSTENNA/XEPLION.

About Mindstate Design Labs

Mindstate Design Labs, formerly known as Kykeon Biotechnologies, is a healthcare company specializing in the development of psychedelic therapeutics for mental health, utilizing AI and machine learning.

report flag Report inaccurate information

People similar to David Hough

Paul Wren

Chief Scientific Officer @ Mindstate Design Labs

Jessica Smith Beaver

Head of Regulatory Affairs @ Mindstate Design Labs

Jessica Smith Beaver is the Head of Regulatory Affairs, with a strong background in pharmacokinetics and drug metabolism, and extensive experience in regulatory roles across various pharmaceutical companies.

Tom Richardson

Head of Medicinal Chemistry @ Mindstate Design Labs

Tom Richardson is the Head of Medicinal Chemistry with over 20 years of experience, specializing in the development of T-Type calcium channel inhibitors and holding a PhD in Organic Chemistry from The Ohio State University.

Unlock exclusive insights

Sign up to reveal more information.

loader Sign up for free